Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.
❓ Unknown
Targeted Therapies Improve Survival Rates in Kidney Cancer Patients
3d ago
October 28, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A clinical trial led by Roswell Park Comprehensive Cancer Center demonstrated that the combination of bevacizumab and pazopanib significantly improves survival rates in kidney cancer patients. This study, published in The Lancet Oncology, highlights advancements in cancer treatment. Such medical advancements could impact healthcare discussions in Iran, especially regarding access to innovative therapies.
🔍 Quick Context Guide
💡 Bottom Line:
The combination of bevacizumab and pazopanib offers hope for improved kidney cancer survival rates, which could influence treatment practices worldwide.
👥 Key Players
Saby George, M.D., FACP
MENTIONED
Principal Investigator and Professor of Oncology
"He leads significant cancer research that could influence treatment options in Iran."
Roswell Park Comprehensive Cancer Center
MENTIONED
Research Institution
"A leading cancer research center that contributes to advancements in oncology, potentially impacting global treatment protocols."
📰 What Happened
A clinical trial showed that combining two targeted therapies, bevacizumab and pazopanib, significantly improves survival rates for kidney cancer patients. This research was published in a prominent medical journal, indicating its importance in cancer treatment advancements.
- The trial demonstrated improved progression-free and overall survival rates.
- The study was published in The Lancet Oncology, a reputable medical journal.
💡 Why It Matters
🇮🇷 For Iran: Improved cancer treatment options could enhance healthcare quality in Iran, where access to advanced therapies is limited.
🌍 Regional: Advancements in cancer treatment can inspire similar research initiatives in the region, potentially improving healthcare systems.
🌐 International: This research may lead to new treatment protocols that could be adopted internationally, affecting global cancer care standards.
📚 Background
Kidney cancer is a significant health issue, and targeted therapies represent a promising approach to treatment. Understanding these advancements is crucial for patients and healthcare providers.
Cancer treatment advancements
Targeted therapies in oncology
📡 Source:
NEUTRAL
📊 Confidence:
70%
The study is published in a reputable journal, suggesting a high level of scientific scrutiny and credibility.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
10 min ago •
Trump: Negotiations with Iran are progressing well but are not trustworthy
11 min ago •
Collapse of Family Ties; A Factor in Increasing Anxiety and Risky Behaviors
11 min ago •
President of Alborz Azad University: The University Must Play a Role in Connecting Religious Knowledge…
12 min ago •
Education Ministry's Measures for Martyr and Veteran Families Lacking Access to Martyr Schools
12 min ago •